CG Oncology, Inc.·4

Apr 16, 4:15 PM ET

Kasturi Vijay 4

4 · CG Oncology, Inc. · Filed Apr 16, 2026

Research Summary

AI-generated summary of this filing

Updated

CG Oncology (CGON) CMO Kasturi Vijay Receives Equity Award

What Happened

  • Kasturi Vijay, Chief Medical Officer of CG Oncology, received a grant/award (derivative) covering 79,216 shares on 2026-04-15. The reported acquisition price is $0.00, indicating an equity award (option-like instrument) rather than an open-market purchase or sale.

Key Details

  • Transaction date: 2026-04-15; Form 4 filed 2026-04-16 (timely)
  • Reported amount: 79,216 shares; reported price per share: $0.00 (derivative award)
  • Vesting: 1/48th of the shares subject to the option vest monthly beginning April 15, 2026, contingent on continuous service through each vesting date (footnote)
  • Shares owned after transaction: not specified in the provided filing details
  • Transaction code: A (grant/award/other acquisition)

Context

  • This was a compensation-related derivative grant (an option-like award) that vests over four years; it is not an open-market purchase or sale and does not reflect an immediate cash outlay or sale of stock. Such grants are common for executive compensation and should be viewed as part of standard equity incentives rather than a direct buy/sell signal.

Insider Transaction Report

Form 4
Period: 2026-04-15
Kasturi Vijay
Chief Medical Officer
Transactions
  • Award

    Employee Stock Option (Right to Buy)

    [F1]
    2026-04-15+79,21679,216 total
    Exercise: $67.68Exp: 2036-04-14Common Stock (79,216 underlying)
Footnotes (1)
  • [F1]1/48th of the shares subject to the option vest monthly following April 15, 2026, the vesting commencement date, subject to the Reporting Person's continuous service to the Issuer through each vesting date.
Signature
/s/ Joshua F. Patterson, Attorney-in-Fact for Vijay Kasturi|2026-04-15

Documents

1 file
  • 4
    ownership.xmlPrimary

    4